Sign up USA
Proactive Investors - Run By Investors For Investors
Market: AIM:AKR
52-week High/Low: 114.00p / 10.50p
Sector: Health Care, Equipment & Services
Market Cap: 35.25M
Akers Biosciences, Inc.

Akers Biosciences, Inc.

Akers Biosciences, Inc. develops, manufactures, and distributes rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician.  We have developed several proprietary platform technologies that provide us with product development flexibility.  Our goal is to always deliver accurate, single-patient results in a time- and...

Akers Biosciences, Inc.

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Akers Biosciences, Inc.

Akers Biosciences, Inc. Snapshot

Akers Bio’s business is positioned at the forefront of a major drive in global healthcare to reduce costs, accelerate diagnoses and deliver health information directly to users.

Akers Bio is transforming traditional healthcare testing through the introduction of cutting edge technologies which replace existing procedures with quicker, easier tests that facilitate faster health decision-making.

Our disruptive new testing technologies can save hundreds of thousands – to millions – of dollars for many organizations through faster screening, while at the same time improving the quality of patient care.

Some of our tests are designed to deliver rapid information directly to the user about his or her own health and wellness via a simple breath test, enabling them to take greater control over their personal wellbeing, and even allowing users to monitor trends in their health via their own mobile device, using Akers Bio’s innovative apps.

Utilizing our proprietary technologies, Akers Bio has a pipeline of new tests in development, designed to help manage some of the most prevalent and resource-intensive conditions including respiratory, infectious and cardiac diseases.

Akers Bio has a growing product portfolio, a growing sales and distribution capability, and is addressing a large and growing global market for rapid health information.


Innovative Products Derived from Cutting Edge Technologies

Akers Bio’s products are based on proprietary, cutting edge technologies developed by Akers Bio. We develop, manufacture and sell time- and cost -efficient, single use devices – many of which can be utilized almost anytime, anywhere. We believe that our products facilitate more convenient and frequent point-of-care testing, which may ultimately save or improve the overall quality of individuals’ lives. We make tests designed for Clinical use as well as tests for personal and commercial Safety. We also have an expanding range of tests under the Akers Wellness™ line that enable clinicians and consumers to easily test, monitor and track aspects of their health over time. Read more about these, as well as our pipeline of Tests in Development.

Clinical Diagnostics

Our rapid diagnostic tests, specifically designed for medical clinicians, help facilitate or rule-out diagnoses to allow for faster treatment decisions. They also provide affordable mass screening solutions for key infectious diseases without the use of expensive equipment or lengthy test procedures. Current clinical diagnostic tests include:

Safety Diagnostics

Our safety products improve the ability of individuals, corporations, and law enforcement agencies to monitor the presence of substances within the human body that may adversely impact the ability to safely perform tasks such as driving or operating machinery. Our products facilitate testing on a more consistent or frequent basis because they are simple to perform, inexpensive and provide rapid results. Current clinical diagnostic tests include:

Akers Wellness products

The products within our Akers Wellness™ line enable health professionals and consumers to test, monitor and track aspects of their health over time. Several of our tests utilize patented technology to enable rapid testing using only breath. Additionally, some of our Akers Wellness™ tests connect directly to your Bluetooth-enabled iOS/Android reading device, enabling you to track your results via our BreathScan™ mobile app. Current Akers Wellness™ products include:

Tests in development

Utilizing our proprietary technologies, Akers Bio has a pipeline of new tests in development, designed to help manage some of the most prevalent and resource-intensive conditions including respiratory, infectious and cardiac diseases. Our current pipeline includes:

(Note that these tests are not currently available and have not been approved for use by the US FDA or any other approval body)

Richard C. Tarbox III
Interim Non-executive Chairman

Richard Tarbox combines over 40 years of management experience in the medical device and diagnostics sector. Richard presently serves as a registered investment banker at Aquilo Partners, L.P., focusing his practice on the needs of clients in the life science tools and diagnostics sectors. Previously, he held executive roles, primarily in business development and operations management, with Becton Dickinson, Thermo Fisher Scientific, Cardinal Health, Baxter International Inc. and American Hospital Supply Corporation. He has also served a number of companies in the industry as an officer and member of the board of directors including Alverix, Inc., Quidel Corporation, ClearData Networks, Bioseparations Inc., Metrika Laboratories, DenOptix, Inc. and Ostex International Inc. Richard holds a Bachelor’s degree in Clinical Psychology from the University of Washington and a Master’s degree in Business Management from the Kellogg School of Management at Northwestern University.


John J. Gormally
Chief Executive Officer

John Gormally is an experienced medical technology specialist with a career spanning more than 30 years with the global medical technology company Becton Dickinson. He has considerable experience of managing large distribution networks as well as direct sales to hospitals and reference laboratories. Prior to joining Akers Bio in 2015 and its board of directors in 2017, John served as Vice President, US Region Business Leader of Preanalytical Systems at Becton Dickinson where he led a multi-functional team of 92 associates in a business unit which contributed annual revenues of over $650 million. Prior to that role, John was Vice President, Worldwide Sales of Preanalytical Systems, leading a global sales function with 256 associates and annual revenues of $1.1 billion. John first joined Becton Dickinson in 1979 and climbed the sales and management ranks over twenty years within the Medical Surgical, Microbiology/Diagnostics and then Healthcare Systems divisions. John left Becton Dickinson in 1999 for several years to join Bristol-Myers Squibb Company, a global biopharmaceutical business focused on pharmaceutical and nutritional products. There he was accountable for a sales force/operations team of 226, with $450 million in annual revenue. He later joined BEI Medical Systems, a medical device start up, as Vice President, Global Sales and Marketing. John developed a successful commercial strategy and established a profitable business which was sold two years later, in 2003, to Boston Scientific for $95 million. Following the sale, John was recruited back to Becton Dickinson. John holds a B.S. Biology from DeSales University, PA.


Bill J. White
Non-executive Director

Bill White has more than 30 years of experience in financial management, operations and business development. He currently serves as Chief Financial Officer, Treasurer and Secretary of Intellicheck Mobilisa, Inc., a technology company listed on the NYSE MKT. Prior to working at Intellicheck Mobilisa, Inc., he served 11 years as the Chief Financial Officer, Secretary and Treasurer of FocusMicro, Inc. As co-founder of that company, Bill played an integral role in growing the business from the company’s inception to over $36 million in annual revenue in a five-year period. Prior to FocusMicro, he served 15 years in various financial leadership positions in the government sector. Bill started his career in Public Accounting and holds a B.A. Business Administration from Washington State University and is a Certified Fraud Examiner.


Christopher C. Schreiber
Non-executive Director

Christopher Schreiber has over 30 years of experience in the securities industry. As the Managing Director of Capital Markets at Taglich Brothers, Inc., Christopher builds upon his extensive background in capital markets, deal structures, and syndications. Prior to Taglich Brothers, he was a member of the board of directors of Paulson Investment Company, a 40-year-old full service Investment Banking firm. In addition, Christopher serves as a director and partner of Long Island Express North, an elite lacrosse training organization for teams and individuals. He also volunteers on the board of directors for Fox Lane Youth Lacrosse, a community youth program. Christopher holds a Bachelor’s degree in Political Science from John Hopkins University.


Raymond F. Akers Jr., Ph.D.
Non-executive Director

Raymond Akers founded the company in 1989. He has vast experience in the diagnostics industry having co-founded Drug Screening Systems, Inc., a publicly listed company, in 1987 and Akers Medical Technology Inc., in 1984. He was President and Chief Executive Officer of Akers Medical Technology Inc. until 1987 and later Chief Executive Officer and Vice President of Research and Development of Drug Screening Systems, Inc. until the sale of that company in 1989. He holds a Ph.D. in Neurochemistry from Northwestern University. Raymond is the inventor of the company’s platform technologies including Particle ImmunoFiltration Assay (PIFA), the basis for the company’s flagship rapid test for heparin induced thrombocytopenia (HIT).

Company Ownership

Shareholder Name Amount of Shares Owned % of Company
Empery Asset Management, LP 724,000 8.14%
Chubeworkx Guernsey Limited 512,820 5.77%

There are currently 8,891,245 common shares in issue.


Insider Ownership

Director Name Amount % Holding
Thomas J. Knox, Ph.D. (HC), CLU, ChFC, FCPP 478,150 5.39%
Brandon Knox 124,326 1.40%
Robert E. Andrews 48,125 0.54%
Raza Bokhari M.D. 32,083 0.36%
Raymond Akers, Jr. PhD* 0 0.00%

* Dr. Akers does not directly own any shares in the Company, but is classified under AIM Rules as having a beneficial interest in a total of 72,100 shares by virtue of his wife being a trustee of the Akers Family Trust, which holds 70,000 shares, and as a result of her shareholding of 2,100 shares. These holdings represent an aggregate 0.81% of the total voting rights 


Contact Us
Akers Biosciences, Inc.
201 Grove Road
West Deptford, NJ 08086
Tel: +1 (856) 848-8698
Email: [email protected]

Investor Relations

Chris Schreiber
Taglich Brothers, Inc.
790 New York Avenue
Suite 209
Huntington, New York 11743
Tel. +1 917 445 6207
Email: [email protected]

Public Relations

Vigo Communications
180 Piccadilly
London W1J 9HF
Tel. +44 (0)20 7830 9700
Email: [email protected]

US Transfer Agent

VStock Transfer, LLC
77 Spruce Street
Suite 201
Cedarhurst, New York 11516
Tel. +1 212 828 8436 UK

Nominated Adviser & Broker

60 New Broad Street
London EC2M 1JJ
Tel. +44 (0)20 7220 0500

MorisonCogen LLP
150 Monument Road
Suite 500
Bala Cynwyd, Pennsylvania 19004
Tel. +1 267 440 3000

UK Transfer Agent

Capita Asset Services
The Registry
34 Beckenham Road
Beckenham, Kent BR3 4TU
Tel. +44 (0)871 664 0300


Lucosky Brookman LLP
101 Wood Avenue South
Woodbridge, New Jersey 08830
Tel. +1 732 395 4400

Akers Biosciences, Inc. Timeline

May 07 2018
April 26 2018
April 26 2018
April 25 2018
April 12 2018
April 05 2018
April 02 2018

Columns Including AKR


Market Reports Including AKR

Video RSS


Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use